Abstract

Treatment of 125I-labelled high-density lipoprotein ([ 125I]HDL 3) with monospecific polyclonal antibodies against apolipoproteins A-I and A-II resulted in a dose-dependent inhibition of the [ 125I]HDL 3 binding to isolated human small intestine epithelial cells by 25%, and 50%, respectively. Both antibodies also inhibited intracellular degradation of [ 125I]HDL 3 by 80%. Treatment of enterocytes with polyclonal antibody against apolipoprotein A-I binding protein, a putative HDL receptor, inhibited both binding and degradation of [ 125I]HDL 3 by these cells by 50%. Antibodies to apolipoprotein A-I, A-II and apo A-I-binding protein also inhibited [ 125I]HDL 3 binding to cholesterol-loaded cells.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call